MedTrace Logo

Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer

NCT02316340 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2024-01-05

Study results available
· View outcomes & findings →

Summary

This will be a randomized phase II clinical trial of patients with histologic documentation of metastatic colorectal cancer, who have received local and currently approved standard therapies, excluding RGF.

Conditions

Interventions

DRUG

Vorinostat

400mg by mouth daily

DRUG

Hydroxychloroquine

600mg by mouth daily

DRUG

Regorafenib

160 mg by mouth daily

Sponsors & Collaborators

  • The University of Texas Health Science Center at San Antonio

    lead OTHER

Principal Investigators

  • Sukeshi Patel Arora, MD · University of Texas Health Science Center at the Cancer Therapy and Research Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-11
Primary Completion
2018-03-07
Completion
2018-04-16

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02316340 on ClinicalTrials.gov